<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04935255</url>
  </required_header>
  <id_info>
    <org_study_id>TANNED</org_study_id>
    <nct_id>NCT04935255</nct_id>
  </id_info>
  <brief_title>Determining the Clinical Relevance of the inTeraction Between AprepitaNt aNd EtoposiDe</brief_title>
  <acronym>TANNED</acronym>
  <official_title>Determining the Clinical Relevance of the inTeraction Between AprepitaNt aNd EtoposiDe; an Observational Pharmacokinetic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: In pharmacokinetic studies, aprepitant was shown to be a moderate inhibitor of&#xD;
      CYP3A4 activity. Etoposide is metabolised by CYP3A4.&#xD;
&#xD;
      Objective: to investigate the absence of a clinical relevant interaction between aprepitant&#xD;
      and etoposide in TC patients treated with (B)EP.&#xD;
&#xD;
      Study design: A single centre, prospective, paired observational pharmacokinetic study in 12&#xD;
      patients with TC who are treated with etoposide during 5 days in combination with cisplatin&#xD;
      with or without bleomycin conform the standard BEP or EP-protocol and who will be treated&#xD;
      with aprepitant from day 3 until day 7 according to the routine antiemetic protocol. The&#xD;
      effect of aprepitant on etoposide will be investigated within the same patient. In this study&#xD;
      the patient will serve as its own control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Exposure to etoposide</measure>
    <time_frame>24 hours after administration</time_frame>
    <description>Etoposide exposure (AUC0-24hr) with and without cotreatment with aprepitant</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Testicular Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <description>The participating patients are treated according to local standard treatment (consisting of etoposide 100mg/m2 and cisplatin 20 mg/m2 during 5 consecutive days). Anti-emetic treatment with aprepitant will be given during days 3 to 7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling - Pharmacokinetic assessment</intervention_name>
    <description>Two pharmacokinetic assessments will be performed (on day 2 and day 4). Each pharmacokinetic assessment consists of 10 samples (5 ml blood).</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will exist of patients treated at the Radboudumc who are diagnosed&#xD;
        with TC and are treated with (B)EP according to standard treatment guidelines.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with TC who will start or already started treatment with (B)EP&#xD;
&#xD;
          -  Age of at least 18 years&#xD;
&#xD;
          -  Patients from whom it is possible to collect blood samples&#xD;
&#xD;
          -  Patients who are able and willing to give written informed consent prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are co-treated with drugs that could interfere with the metabolism of&#xD;
             etoposide (including drugs classified as a weak, moderate or strong CYP3A4 inhibitor&#xD;
             OR weak, moderate and strong inducers of CYP3A4 according to the table based on the&#xD;
             Flockhart table (Appendix 1) less than 30 days prior to study or during the study.&#xD;
&#xD;
          -  Creatininclearance &lt;40 ml/min&#xD;
&#xD;
          -  Severe liver dysfunction (bilirubin&gt;ULN)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeffrey Strik, PharmD</last_name>
    <phone>+31631136951</phone>
    <email>jeffrey.strik@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nielka van Erp, PhD, PharmD</last_name>
    <phone>+31611417813</phone>
    <email>nielka.vanerp@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aprepitant</keyword>
  <keyword>etoposide</keyword>
  <keyword>pharmacokinetic interaction</keyword>
  <keyword>CYP3A4</keyword>
  <keyword>clinical relevant interaction</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

